Search - tctmd.com

Displaying 1 - 20 of 511

Sort: Relevancy | Date

Side Effects of Statins Might Be Overstated: CTT Collaboration

News Daily News

Side Effects of Statins Might Be Overstated: CTT Collaboration

Michael O'Riordan

February 12, 2026

Oral GLP-1s Provide Benefit in HF Patients: SOUL Subanalysis

News Daily News

Oral GLP-1s Provide Benefit in HF Patients: SOUL Subanalysis

February 06, 2026

CHOICE-2 Bolsters Intra-arterial Lytics After Stroke Thrombectomy

News Conference News ISC 2026

CHOICE-2 Bolsters Intra-arterial Lytics After Stroke Thrombectomy

February 06, 2026

Nearly 150 Million US Adults Eligible for CKM Syndrome Meds

News Daily News

Nearly 150 Million US Adults Eligible for CKM Syndrome Meds

February 02, 2026

TCTMD’s Top 10 Most Popular Stories for January 2026

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for January 2026

February 02, 2026

Previewing 30-Year ASCVD Risk May Open Door to Earlier Treatment

News Daily News

Previewing 30-Year ASCVD Risk May Open Door to Earlier Treatment

Yael L. Maxwell

January 21, 2026

January 2026 Dispatch for the CV Team

News Opinion CV Team Dispatch

January 2026 Dispatch for the CV Team

January 16, 2026

Weight Regained Within 18 Months of Stopping GLP-1 Drugs

News Daily News

Weight Regained Within 18 Months of Stopping GLP-1 Drugs

Michael O'Riordan

January 08, 2026

Thrombolysis May Be OK for DOAC-Treated Patients With Ischemic Stroke

News Daily News

Thrombolysis May Be OK for DOAC-Treated Patients With Ischemic Stroke

January 07, 2026

Year in Review: Tirzepatide, Finerenone, and Digitoxin Score Big in Heart Failure

News Daily News

Year in Review: Tirzepatide, Finerenone, and Digitoxin Score Big in Heart Failure

Michael O'Riordan

December 30, 2025

Year in Review: Top Prevention Stories of 2025

News Daily News

Year in Review: Top Prevention Stories of 2025

Michael O'Riordan

December 24, 2025

SURPASS-CVOT Published: Large Trial Confirms CVD Efficacy of Tirzepatide

News Daily News

SURPASS-CVOT Published: Large Trial Confirms CVD Efficacy of Tirzepatide

Michael O'Riordan

December 18, 2025

Patients With Obesity Get Biggest Benefit from Evolocumab: FOURIER

News Daily News

Patients With Obesity Get Biggest Benefit from Evolocumab: FOURIER

Michael O'Riordan

December 12, 2025

WHO Endorses Treating Obesity in Adults With GLP-1s

News Daily News

WHO Endorses Treating Obesity in Adults With GLP-1s

December 01, 2025

Oral PCSK9 Inhibitor Enlicitide Cuts LDL Cholesterol: CORALreef Lipids

News Conference News AHA 2025

Oral PCSK9 Inhibitor Enlicitide Cuts LDL Cholesterol: CORALreef Lipids

Michael O'Riordan

November 10, 2025

Fish Oil Halves CV Risk in Patients on Dialysis: PISCES

News Daily News

Fish Oil Halves CV Risk in Patients on Dialysis: PISCES

Yael L. Maxwell

November 10, 2025

Triple Agonist Appears Promising for Patients With Severe Hypertriglyceridemia

News Conference News AHA 2025

Triple Agonist Appears Promising for Patients With Severe Hypertriglyceridemia

November 08, 2025

Evolocumab Cuts MACE Risk in Patients Without Prior MI, Stroke: VESALIUS-CV

News Conference News AHA 2025

Evolocumab Cuts MACE Risk in Patients Without Prior MI, Stroke: VESALIUS-CV

Michael O'Riordan

November 08, 2025

CRISPR-Cas9 Gene-Editing Therapy Shows Early Promise for Dyslipidemia

News Conference News AHA 2025

CRISPR-Cas9 Gene-Editing Therapy Shows Early Promise for Dyslipidemia

November 08, 2025

Slight Gain in Stroke Protection Seen With DAPT in ViV TAVI

News Daily News

Slight Gain in Stroke Protection Seen With DAPT in ViV TAVI

October 09, 2025

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.